This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Brugada Syndrome
and you are
over 18
years old
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The specific aim of this study is to determine whether hydroquinidine administration can prevent heart from appearance of ventricular arrhythmia detected by the automatic implantable defibrillator (ICD).

Provided treatments

  • Drug: hydroquinidine
  • Drug: placebo (sugar)
Tris trial is registered with FDA with number: NCT00927732. The sponsor of the trial is Nantes University Hospital and it is looking for 64 volunteers for the current phase.
Official trial title:
BRD 06/2-D (Quidam) "Evaluation of the Interest of Oral Hydroquinidine Administration to Treat Patients With Brugada Syndrome, High Cardiac Arrhythmic Risk and Implanted With an Implantable Cardioverter Defibrillator"